Expression And Clinical Significance Of TKTL1 Before And After Neoadjuvant Endocrine Therapy For Prostate Cancer

Research Objective : Prostate cancer is a very common malignant tumor in male reproductive system tumors,and the incidence of prostate cancer is increasing in recent years.The early diagnosis and treatment of prostate cancer is related to the prognosis of patients closely.In recent years,studies have found that the anaerobic glycolysis of glucose plays an important role in the occurrence and development of tumors.Transketolase is a key enzyme in the glycolytic pathway,and the subtype of transketolase-like protein 1(Transketolase-like protein 1 TKTL1)has played an important role and has been shown to be expressed in many cancers such as bladder cancer,colorectal cancer,nasopharyngeal carcinoma,breast cancer,throat cancer and so on,but there is no report about expressing in prostate cancer tissues.And no report in China yet.We studied the expression of TKTL1 in prostate cancer tissues before and after neoadjuvant endocrine therapy and the postoperative biochemical recurrence.On the one hand,we evaluated the correlation between TKTL1 expression and clinical features of patients,and evaluated on the other hand.The relationship between the expression of TKTL1 and the postoperative biochemical recurrence in patients with neoadjuvant endocrine therapy.It is of guiding significance for the presentation of new treatment options for patients with prostate cancer and for predicting postoperative recurrence.Research methods: The data of 60 patients undergoing radical prostate cancer resection after neoadjuvant endocrine therapy from January 2010 to August 2017 in the Department of Urology,Qingdao Municipal Hospital were analyzed retrospectively.The paraffin specimens of patients undergoing radical prostate cancer resection before neoadjuvant endocrine therapy and 3 months after neoadjuvant endocrine therapy were collected.The expression of TKTL1 in prostate cancer before and after neoadjuvant endocrine therapy was detected by immunohistochemistry,and the relationship between TKTL1 and clinicopathological factors was studied by single factor variance analysis and chi-square test.The serum PSA level was followed up before and after operation,and the relationship between TKTL1 expression and prognosis was analyzed by chi-square test and kaplan-Meier method.Research results: Immunohistochemistry was used to detect the expression of TKTL1 in prostate cancer tissues before and after neoadjuvant endocrine therapy.The expression of TKTL1 was positive in prostate cancer patients before neoadjuvant endocrine therapy.The staining intensity was(++);neoadjuvant endocrine therapy After TKTL1 expression decreased,the staining intensity was(+).For prostate cancer patients with Gleason score greater than 7 points,blood PSA levels >10 mmol/L,and clinical stage III prostate cancer,the expression level of TKTL1 was significantly higher than that of the control group.The difference was statistically significant(P<0.05),but not related to patient age.At the same time,the postoperative biochemical recurrence rate of patients showed that the postoperative biochemical recurrence rate was significantly higher in the TKTL1 high expression group than in the low expression group(P<0.05).Research conclusion: The decrease in the expression level of TKTL1 in prostate cancer tissues after neoadjuvant endocrine therapy is related to the Gleason score,lymph node metastasis,clinical stage,and PSA level of the patient,regardless of the age of the patient.The high expression of TKTL1 is positively correlated with the postoperative biochemical recurrence rate of prostate cancer.In the treatment of prostate cancer,according to the above characteristics,it can help to evaluate the effect of neoadjuvant endocrine,prognosis and guide the next treatment.It may also provide a theoretical basis for studying the occurrence,development,recurrence and metastasis of prostate cancer in the TKTL1 signaling pathway.